SynthesisThe Cochrane database of systematic reviews2012
Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease.
Synthesis in The Cochrane database of systematic reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 6 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Laser therapy for retinopathy in sickle cell disease.The Cochrane database of systematic reviews · 2022Pooled it
- Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease.The Cochrane database of systematic reviews · 2021Pooled it
- Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease.The Cochrane database of systematic reviews · 2017Pooled it
- The Italian Society for Pediatric Nephrology (SINePe) consensus document on the management of nephrotic syndrome in children: Part I - Diagnosis and treatment of the first episode and the first relapse.Italian journal of pediatrics · 2017Pooled it
- Laser therapy for retinopathy in sickle cell disease.The Cochrane database of systematic reviews · 2015Pooled it
- A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.Expert review of hematology · 2015Pooled it
- Sickle cell disease: a comprehensive program of care from birth.Hematology. American Society of Hematology. Education Program · 2019Review
- Article
- Preventive Care Delivery to Young Children With Sickle Cell Disease.Journal of pediatric hematology/oncology · 2016Article
- Precipitating factors and targeted therapies in combating the perils of sickle cell disease--- A special nutritional consideration.Nutrition & metabolism · 2016Review
- Sickle cell disease: management options and challenges in developing countries.Mediterranean journal of hematology and infectious diseases · 2013Article
Corrections and comments
- Updated by
- Update of
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
Abstract
backgroundPeople with sickle cell disease are particularly susceptible to infection. Infants and very young children are especially vulnerable, and the 'Co-operative Study of Sickle Cell Disease' observed an incidence rate of 10 per 100 patient years of pneumococcal septicaemia in children under the age of three. Vaccines, including customary pneumococcal vaccines, may be of limited use in this age group. Therefore, prophylactic penicillin regimens may be advisable for this population.
objectivesTo assess the effects of prophylactic antibiotic regimens for preventing pneumococcal infection in children with sickle cell disease. SEARCH
methodsWe searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register, which is comprised of references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.Date of the most recent search: 28 March 2012. SELECTION CRITERIA: All randomised or quasi-randomised controlled trials comparing prophylactic antibiotics to prevent pneumococcal infection in children with sickle cell disease with placebo, no treatment or a comparator drug. DATA COLLECTION AND ANALYSIS: Both authors independently extracted data and assessed trial quality. MAIN
resultsFive trials were identified by the initial search, of which three trials met the inclusion criteria. All of the included trials showed a reduced incidence of infection in children with sickle cell disease (SS or Sβ0Thal) receiving prophylactic penicillin. In trials which investigated initiation of penicillin on risk of pneumococcal infection, the odds ratio was 0.37 (95% CI 0.16 to 0.86), while for withdrawal the odds ratio was 0.49 (95% CI 0.09 to 2.71). Adverse drug effects were rare and minor. Rates of pneumococcal infection were found to be relatively low in children over the age of five. AUTHORS'
conclusionsProphylactic penicillin significantly reduces risk of pneumococcal infection in children with homozygous sickle cell disease, and is associated with minimal adverse reactions. Further research may help to determine the ideal age to safely withdraw penicillin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.